Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1001 participants
OBSERVATIONAL
2008-02-29
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Methods:
Platelet reactivity on clopidogrel and aspirin therapy is measured before PCI with VerifyNow (Accumetrics Inc.,San Diego, CA, USA) P2Y12 or aspirin assay respectively in 1000 consecutive patients from 20 centers in France undergoing coronary angioplasty with stent.
Exclusion criteria are:
Acute myocardial infarction, treatment with vitamin K antagonists and the use of antiGP2b3a before PCI. All patients are pre-treated with clopidogrel and aspirin. Non-response to aspirin or clopidogrel is determined according to the result of the VerifyNow assay (cut off : \< 15 % for P2Y12 and \> 550 ARU for aspirin). The primary end point is the occurrence of definite or probable stent thrombosis (ARC definition) and the secondary end-points include global and cardio-vascular mortality, non fatal myocardial infarction and major bleeding. A clinical evaluation is scheduled at discharge and by telephone contact at one month and one year.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of a XIENCE V® Endoprothesis Used for Coronary Angioplasty, for LPPR (List of Reimbursable Products and Services) Indications in Patients Monitored for 2 Years in France
NCT00987506
BioFreedom French Registry
NCT03745066
A Feasibility Study of the Cordis Neurovascular Self Expanding Stent System in Intracranial Arteries
NCT00349908
Biofreedom Prospective Multicenter Observational Registry
NCT03045848
French eCLIPs™ Efficacy and Safety Investigation
NCT05330897
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Acute myocardial infarction
* No aspirin and clopidogrel pretreatment
* Use of AVK
* Aspirin or clopidogrel contre-indication
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic
INDUSTRY
Boston Scientific Corporation
INDUSTRY
Cordis Corporation
INDUSTRY
Abbott
INDUSTRY
Association Pour le Développement des Soins Cardiologiques de la ville de Chartres
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
RANGE Gregoire
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
gregoire rangé
Role: PRINCIPAL_INVESTIGATOR
GACI
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
cardiology unit / Les hopitaux de Chartres
Chartres, Eure Et Loir, France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Range G, Yayehd K, Belle L, Thuaire C, Richard P, Cazaux P, Barbou F, Koning R, Chassaing S, Teiger E, Berthier R, Decomis MP, Claudel JP, Delarche N, Brunel P, De Poli F, Dupouy P, Beygui F, Albert F, Collet JP, Montalescot G; VERIFRENCHY investigators. Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY). Arch Cardiovasc Dis. 2014 Apr;107(4):225-35. doi: 10.1016/j.acvd.2014.03.004. Epub 2014 Apr 29.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CPP n°2008-N2
Identifier Type: -
Identifier Source: secondary_id
AFFSAPS 2008-A00411-54
Identifier Type: -
Identifier Source: secondary_id
VERIfynow FRENCH registrY
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.